FXS5626 tablets, a subsidiary of Fosun Pharmaceuticals (600196.SH), were approved for clinical trials

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, the company's holding subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”) received approval from the State Drug Administration to conduct phase II/III adaptive seamless design clinical trials for FXS5626 tablets (original project code: AC-201, “FXS5626” for short) to treat non-segmental vitiligo. Fosun Pharmaceutical Industry plans to carry out clinical research on this drug in China when conditions are met.

According to reports, FXS5626 is an oral small molecule JAK inhibitor (TYK2/JAK1 dual target inhibitor) approved by the company, and the company has exclusive rights to research, develop, produce, register and commercialize this drug within China, Hong Kong and Macau regions. FXS5626 is intended to be mainly used in the field of autoimmune diseases. As of the announcement date (i.e. September 8, 2026, same below), the drug has completed phase II clinical trials for moderate to severe plaque psoriasis in China, and is in phase II clinical trials for non-infectious uveitis in China. As of August 2026, the company's cumulative R&D investment for FXS5626 at this stage is approximately 108 million yuan (including licensing fees; unaudited).